Back to results
US 2006/0068018 A1Published application
Extended release formulation
AssigneeWyeth
InventorsDeborah Sherman, John Clark, John Lamer, Steven White
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeWyeth
InventorsDeborah Sherman, John Clark, John Lamer, Steven White
Estimating the term…
This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
A unit dosage form comprising venlafaxine, the dosage form providing therapeutic blood serum levels of venlafaxine over a period of at least 24 hours.
A unit dosage form comprising venlafaxine, wherein the unit dosage form provides therapeutic blood serum levels characterized by a peak, followed by a protracted, substantially linear decrease.
A unit dosage form comprising venlafaxine, the dosage form providing a Cmax of venlafaxine between 4 and 8 hours after administration to a subject.
A unit dosage form comprising venlafaxine, wherein the unit dosage form provides a peak of venlafaxine between 4 and 8 hours after administration to a subject.
Dependencies are inferred from the claim text.